02:07 PM EDT, 10/22/2025 (MT Newswires) -- Healwell AI (AIDX.TO) this week, in collaboration with vedolizumab manufacturer, Takeda, presented new AI generated and regulatory-grade real-world data (RWD) on vedolizumab dose escalation in ulcerative colitis and Crohn's disease at the United European Gastroenterology Week in Berlin.

The data was generated from Healwell's Darwen platform and discovered improved remission outcomes in patients taking vedolizumab with Crohn's and Ulcerative Colitis under dose-escalation regime of every four weeks instead of the typical eight weeks. It is one of the first examples of using AI to generate regulatory-grade RWD for these types of applications, a Healwell statement said.

Stifel Canada's Justin Keywood sees the news as a validation of the recently acquired Darwen AI within HealWELL's Pentavere unit and demonstrates the practical value of the technology. The collaboration with Takeda also indicates a likely commercial relationship with a high-profile pharma name, he adds.

Stifel has a Buy rating and $3.80 target on the Healwell AI.

Price: 1.38, Change: -0.08, Percent Change: -5.48